The mds Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mds Hub cannot guarantee the accuracy of translated content. The mds and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mds content recommended for you
What hematologic toxicities occur after venetoclax + azacitidine in MDS and how can they be managed?
Featured:
Uwe PlatzbeckerDuring the EHA2021 Virtual Congress, the MDS Hub spoke with Uwe Platzbecker, University of Leipzig Medical Center, Leipzig, DE. We asked, What hematologic toxicities occur after venetoclax + azacitidine in MDS and how can they be managed?
What hematologic toxicities occur after venetoclax + azacitidine in MDS and how can they be managed?
In this podcast, Platzbecker discusses the potential hematologic toxicities associated with the combination of venetoclax and azacitidine, and how to manage these toxicities in patients with high-risk MDS. He highlights the key points of a study presented during EHA2021, including dose modification considerations, overall response rates, infectious complications, and other side effects. Finally, Platzbecker believes this toxicity analysis provides clinically valuable information to doctors and hematologists who are already treating patients with this combination.